Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07311564 · ClinicalTrials.gov registry record · Phase 2
A Study of LAD603 in Adults With Alopecia Areata
A Phase 2 study of Alopecia Areata, sponsored by Almirall, S.A..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
- 1
- Study location
NCT07311564: Recruiting Phase 2 study of Alopecia Areata, sponsored by Almirall, S.A..
NCT07311564 is a Phase 2 study of Alopecia Areata that is actively recruiting participants, run by Almirall, S.A.. The registered enrollment target is 136 participants, below the 1,950-participant average among 26 other Alopecia Areata trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07311564, a Phase 2 study of Alopecia Areata, is actively recruiting participants, sponsored by Almirall, S.A..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
- 1
- Study location
Study Summary
The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA). The study will also evaluate the safety, pharmacokinetics (PK), immunogenicity and pharmacodynamic (PD) biomarkers of LAD603.
Primary Outcome
The SALT score is the sum of percentage of hair loss in all areas with a maximum score of 100 (higher score indicates greater hair loss).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG LAD603
Study Locations (1)
Nebraska
- Investigator Site 1 - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2025-12-17 |
| Est. Completion | 2027-11-21 |
| Phase | Phase 2 |
What NCT07311564 shows while recruiting
NCT07311564 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 1,950-participant average among 26 other Alopecia Areata trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Alopecia Areata appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07311564 reports a single indexed study location in Nebraska.
Frequently Asked Questions
What is clinical trial NCT07311564 about?
NCT07311564 is a clinical study titled "A Study of LAD603 in Adults With Alopecia Areata". The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA). The study will also evaluate the safety, pharmacokinetics (PK), immunogenicity and pharmacodynamic (PD) biomarkers of LAD603.
What is the current status of trial NCT07311564?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2025-12-17. Estimated completion is 2027-11-21.
What conditions does trial NCT07311564 study?
This clinical trial studies the following conditions: Alopecia Areata.
What interventions are being tested in trial NCT07311564?
The interventions under investigation include: Placebo (OTHER), LAD603 (DRUG).
Who is sponsoring clinical trial NCT07311564?
This trial is sponsored by Almirall, S.A., which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07311564 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia Areata
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07311564's enrollment target sits among peer trials
136 13th of 26 higher than 14 of 26 other Alopecia Areata trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alopecia Areata trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
RECRUITING · Phase 2
-
Dupilumab in the Treatment of Pediatric Alopecia Areata
RECRUITING · Phase 2
-
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
RECRUITING · Phase 2
-
Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
RECRUITING · Phase 2
-
Regeneron AA Multicenter (Dupilumab)
RECRUITING · Phase 2
-
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI